These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25279293)

  • 1. Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome.
    Maie K; Yokoyama Y; Kurita N; Minohara H; Yanagimoto S; Hasegawa Y; Homma M; Chiba S
    Springerplus; 2014; 3():501. PubMed ID: 25279293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
    Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
    Spina M; Nagy Z; Ribera JM; Federico M; Aurer I; Jordan K; Borsaru G; Pristupa AS; Bosi A; Grosicki S; Glushko NL; Ristic D; Jakucs J; Montesinos P; Mayer J; Rego EM; Baldini S; Scartoni S; Capriati A; Maggi CA; Simonelli C;
    Ann Oncol; 2015 Oct; 26(10):2155-61. PubMed ID: 26216382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
    Kishimoto K; Kobayashi R; Hori D; Sano H; Suzuki D; Kobayashi K
    Anticancer Res; 2017 Oct; 37(10):5845-5849. PubMed ID: 28982910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of febuxostat 10 mg for the prevention of hyperuricemia associated with tumor lysis syndrome (TLS) in Japanese patients with non-Hodgkin's lymphoma
.
    Yasu T; Kobayashi S; Horii M; Kurokawa Y
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1009-1012. PubMed ID: 27641217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.
    Takai M; Yamauchi T; Fujita K; Lee S; Ookura M; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2014 Oct; 8(4):1523-1527. PubMed ID: 25202361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
    Takai M; Yamauchi T; Matsuda Y; Tai K; Ikegaya S; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2015 May; 9(5):2119-2125. PubMed ID: 26137024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
    Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
    J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.